On the 18th May NICE released draft guidance which recommends dapagliflozin as a treatment option for people with symptomatic chronic heart failure with mildly reduced or preserved ejection fraction.
Evidence from a clinical trial shows that adding dapagliflozin to standard care with diuretic therapy reduces the combined risk of dying from cardiovascular causes or the likelihood of being hospitalised with heart failure.
Dapagliflozin is the first NICE recommended treatment which can delay the disease process and improve symptoms.
Symptoms of heart failure commonly include breathlessness, fatigue and abdominal and/or ankle swelling.
The NICE press release can be found here.